📊 LFMDP Key Takeaways
Is LFMDP a Good Investment? Thesis Analysis
LifeMD demonstrates strong fundamental growth with 25.3% YoY revenue expansion and exceptional 85.7% gross margins characteristic of scalable healthcare services. However, negative 4.0% operating margins and reliance on non-operating gains for profitability raise sustainability concerns, partially offset by positive free cash flow generation and a strong $36.8M cash position.
Why Buy LFMDP? Key Strengths
- Exceptional 85.7% gross margin indicating strong pricing power, operational efficiency, and attractive unit economics in healthcare services
- Robust revenue growth of 25.3% YoY with net income growing faster at 27.6%, demonstrating positive operating leverage potential as company scales
- Fortress balance sheet with $36.8M cash, 0.69x debt-to-equity ratio, and positive $6.4M free cash flow providing financial runway during expansion phase
- High ROE of 62% and ROA of 20.4% suggest underlying business quality and efficient capital deployment despite near-term profitability challenges
LFMDP Investment Risks to Consider
- Critical profitability issue: negative 4.0% operating margin indicates core operations are unprofitable; $22M+ gap between operating loss and net income suggests reliance on non-operating gains rather than sustainable earnings
- Negative 5.6x interest coverage ratio demonstrates inability to service debt from operating cash flow, creating debt sustainability risk if non-operating gains decline
- 3.3% free cash flow margin significantly lags 7.4% net margin, indicating quality of earnings concerns and potential divergence between reported profits and actual cash generation
- Current ratio of 1.25x is modest despite high absolute cash, suggesting tight operating liquidity if non-operating cash sources diminish
Key Metrics to Watch
- Operating margin trajectory - must show clear path to positive operating profitability to validate business model sustainability
- Interest coverage ratio improvement - critical indicator of whether operations can support debt obligations independently of non-operating gains
- Operating cash flow to net income ratio - monitor quality and sustainability of earnings conversion to actual cash
- Source and sustainability of non-operating gains - identify whether these are one-time items or recurring favorable accounting treatments
LFMDP Financial Metrics
💡 AI Analyst Insight
The relatively thin 3.3% FCF margin may limit capital allocation flexibility.
LFMDP Profitability Ratios
LFMDP vs Default Sector
How LifeMD, Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LFMDP Overvalued or Undervalued?
Based on fundamental analysis, LifeMD, Inc. has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LFMDP Balance Sheet & Liquidity
LFMDP 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: LifeMD, Inc.'s revenue has grown significantly by 109% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.60 indicates the company is currently unprofitable.
LFMDP Growth Metrics (YoY)
LFMDP Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $53.3M | -$183.8K | $-0.02 |
| Q2 2025 | $50.7M | -$690.1K | N/A |
| Q1 2025 | $44.1M | $1.4M | N/A |
| Q3 2024 | $38.6M | -$5.1M | N/A |
| Q2 2024 | $35.9M | -$6.7M | N/A |
| Q1 2024 | $33.1M | -$4.0M | N/A |
| Q3 2023 | $31.4M | -$6.1M | N/A |
| Q2 2023 | $30.5M | -$6.7M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
LFMDP Capital Allocation
LFMDP SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for LifeMD, Inc. (CIK: 0000948320)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LFMDP
What is the AI rating for LFMDP?
LifeMD, Inc. (LFMDP) has an AI rating of BUY with 58% confidence, based on fundamental analysis of SEC EDGAR filings.
What are LFMDP's key strengths?
Claude: Exceptional 85.7% gross margin indicating strong pricing power, operational efficiency, and attractive unit economics in healthcare services. Robust revenue growth of 25.3% YoY with net income growing faster at 27.6%, demonstrating positive operating leverage potential as company scales.
What are the risks of investing in LFMDP?
Claude: Critical profitability issue: negative 4.0% operating margin indicates core operations are unprofitable; $22M+ gap between operating loss and net income suggests reliance on non-operating gains rather than sustainable earnings. Negative 5.6x interest coverage ratio demonstrates inability to service debt from operating cash flow, creating debt sustainability risk if non-operating gains decline.
What is LFMDP's revenue and growth?
LifeMD, Inc. reported revenue of $194.1M.
Does LFMDP pay dividends?
LifeMD, Inc. pays dividends, with $3.1M distributed to shareholders in the trailing twelve months.
Where can I find LFMDP SEC filings?
Official SEC filings for LifeMD, Inc. (CIK: 0000948320) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LFMDP's EPS?
LifeMD, Inc. has a diluted EPS of $0.25.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LFMDP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, LifeMD, Inc. has a BUY rating with 58% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is LFMDP stock overvalued or undervalued?
Valuation metrics for LFMDP: ROE of 62.0% (sector avg: 15%), net margin of 7.4% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy LFMDP stock in 2026?
Our dual AI analysis gives LifeMD, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LFMDP's free cash flow?
LifeMD, Inc.'s operating cash flow is $8.3M, with capital expenditures of $1.9M. FCF margin is 3.3%.
How does LFMDP compare to other Default stocks?
Vs Default sector averages: Net margin 7.4% (avg: 12%), ROE 62.0% (avg: 15%), current ratio 1.25 (avg: 1.8).